Essity AB stock (SE0009922164): hygiene specialist in focus after latest quarterly figures

Essity AB, the Swedish hygiene and health group behind brands such as TENA and Zewa, recently presented updated quarterly results that highlighted ongoing profitability improvements and portfolio streamlining in a challenging cost environment, according to a company release published in late April 2026 on its investor relations site Essity investor update as of 04/26/2026. The group continues to emphasize price and mix effects, cost savings and brand strength in categories such as incontinence products and consumer tissue.

On the same occasion, Essity reiterated its focus on improving margins and cash flow after several years of volatile raw material and energy prices, which have affected the broader hygiene and paper industry, according to statements summarized on the company website Essity press information as of 04/26/2026. For US readers, the stock represents an international play on everyday hygiene demand, with listing in Stockholm and secondary trading over the counter in the United States.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

Essity AB: core business model

Essity AB emerged in 2017 as a spin-off from the Swedish group SCA and has since positioned itself as a global player in hygiene and health, supplying tissue, incontinence and professional hygiene products used on a daily basis across households, hospitals, care homes and workplaces, according to company background information released in 2023 on its corporate site Essity corporate profile as of 11/02/2023. The company generates revenue by selling branded products and solutions through retail channels, healthcare institutions and business-to-business partners around the world.

The business model is built on a combination of well-known consumer brands and professional offerings, with product categories including consumer tissue, incontinence care, feminine care and medical solutions for wound care and compression therapy, as well as dispensers and services for public and commercial washrooms, according to product descriptions from the group’s portfolio overview Essity brands overview as of 10/15/2024. By focusing on segments with recurring demand and relatively low substitution risk, Essity seeks to achieve stable cash flows, while innovation and premiumization aim to support pricing power.

In the context of its core model, Essity has announced targeted portfolio measures in recent years, including disposals of non-core operations in order to sharpen its strategic focus and improve margins, according to a divestment announcement from 2024 that outlined the sale of certain tissue assets in Latin America Essity press release as of 06/12/2024. The group continues to invest in capacity upgrades and efficiency improvements, while selective acquisition activity has aimed at strengthening positions in medical solutions and incontinence care.

Main revenue and product drivers for Essity AB

Essity’s revenue is primarily driven by three broad business areas: consumer goods, professional hygiene and medical solutions, with the largest contribution traditionally coming from tissue and incontinence products sold under brands such as TENA and Zewa, as described in its annual report for 2024 published in early 2025 Essity annual report 2024 as of 02/15/2025. Consumer tissue, including toilet paper, kitchen rolls and facial tissue, benefits from high volumes and broad retail distribution, while incontinence products address demographic trends such as an aging population.

Professional hygiene, marketed to businesses and public sector institutions, adds an additional revenue layer, with products like dispensers, hand towels and soaps often supplied under long-term customer relationships. This business can be sensitive to occupancy levels in offices, hotels and public venues, but it also offers opportunities for differentiated solutions and service contracts that enhance customer loyalty, according to management commentary in the 2024 full-year results presentation Essity FY 2024 presentation as of 02/15/2025.

In medical solutions, Essity generates sales with advanced wound care, compression therapy and orthopedics, targeting healthcare systems in Europe, North America and other regions. These products are often reimbursed by public or private insurers and may require clinical evidence and regulatory approvals, which can lengthen product cycles but also create barriers to entry for competitors, according to the medical segment overview provided on the company’s health care information pages Essity medical solutions profile as of 09/30/2024. The company sees potential in combining medical expertise with its hygiene know-how, for instance in wound care where infection control and material science intersect.

Geographically, Essity derives a significant share of its revenue from Europe, but North America and emerging markets such as Latin America and parts of Asia represent important growth drivers, particularly for premium incontinence products and professional hygiene services. The group has emphasized that investments in innovation, e-commerce channels and sustainability-focused products, including recycled fiber solutions, are designed to support long-term demand, according to sustainability reporting that highlighted a £30 million recycled fiber facility project in the United Kingdom British Chambers of Commerce article as of 09/18/2024.

Why Essity AB matters for US investors

For US investors, Essity AB represents exposure to a European-based leader in hygiene and health products with a diversified international footprint that includes North American operations. While the primary listing is on Nasdaq Stockholm in Swedish krona, the stock can be accessed via international brokers and over-the-counter trading lines in the United States, offering a way to complement domestic consumer staples holdings with a non-US issuer, according to trading information from major broker platforms updated in 2025 Nasdaq US market data as of 12/12/2025.

The relevance for US-based portfolios also comes from Essity’s positioning in categories with structural demand drivers, such as aging populations and increasing hygiene awareness, which are observable trends in the United States as well as globally. The company’s presence in professional hygiene in North America means that it participates in demand from US offices, schools, healthcare facilities and hospitality venues, linking its revenue partly to the health of the US service economy, according to regional commentary in its North America segment highlights released alongside the 2024 annual results Essity North America highlights as of 02/15/2025.

From a portfolio construction angle, Essity’s stock may behave differently from US consumer names because of its currency exposure, European regulatory backdrop and specific cost drivers such as European energy and pulp prices. For investors focusing on defensive characteristics, the combination of everyday product usage, strong brands and an emphasis on cost efficiency may be of interest, whereas others might focus on the growth prospects in medical solutions and incontinence care. Ultimately, any allocation decision would depend on individual risk tolerance, return expectations and the ability to manage currency and regional diversification within an overall strategy.

Conclusion

Essity AB stands out as a global hygiene and health company with a portfolio spanning consumer tissue, incontinence care, professional hygiene and medical solutions, anchored by well-known brands and a broad international footprint. Recent quarterly updates have underlined management’s focus on strengthening margins and simplifying the portfolio amid cost volatility, while investments in innovation and sustainability are intended to support long-term competitiveness. For US investors, the stock offers an avenue to gain exposure to structural trends such as aging populations and rising hygiene standards via a European-listed issuer whose revenues extend into North America and other regions. Whether Essity fits an individual strategy will depend on views regarding currency risk, regional diversification and the balance between defensive characteristics and growth ambitions in healthcare-adjacent segments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.